News & Events
-
October 19, 2020 - October 19, 2020
Workshop: RDCA-DAP 2020 Virtual Workshop
Join us for the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) annual workshop and learn more about:
– RDCA-DAP’s first year progress and development
– How RDCA-DAP will work to accelerate rare disease drug development
– How the platform works: improved ability to search and sort data
– Case studies on how sharing patient-level data accelerates understanding of rare diseases
– Ways to get involved and the benefits of engaging with RDCA-DAPMonday, October 19, 11 a.m. – 3:30 p.m. ET. Register now.
- August 11, 2020
- August 11, 2020
-
July 30, 2020
C-Path Partners with CHDR to Expand Global Collaborations
The Critical Path Institute and the Centre for Human Drug Research (CHDR) have joined forces to expand global collaborations for both organizations. The initiative brings together stakeholders from each side with the objective of increasing actionable solutions for drug development and public health. The partnership allows CHDR to become involved in other areas of interest... -
July 22, 2020
C-Path’s PSTC, D-RSC Receive Positive FDA Response for Drug-Induced Skeletal Muscle Injury Biomarkers
Safety biomarkers aim to provide an additional tool for detecting acute drug-induced skeletal muscle injury in phase 1 clinical trials.
TUCSON, Ariz., July 22, 2020 — Critical Path Institute (C-Path) announced today that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) in the U.S. Food and Drug Administration (FDA) issued a positive response to the Letter of Intent (LOI) developed by C-Path’s Predictive Safety Testing Consortium (PSTC) and Duchenne Regulatory Science Consortium (D-RSC), for a panel of four safety biomarkers of acute drug-induced skeletal muscle injury.
